Are you a manufacturer of infant formula? Do you plan to innovate your portfolio with new ingredients? If the logistics for obtaining a marketing authorization for your new ingredients are what’s holding you back, then a&r may be just the partner for you. Our Clinical Research team has extensive experience in clinical trials for [...]
About Emilie-Marie VieubleThis author has not yet filled in any details.
So far Emilie-Marie Vieuble has created 175 blog entries.
Calls are open for consultation on the new EFSA guidance on nano-particles and the nutrient definition. EFSA's Scientific Committee has launched an open consultation on its draft EFSA Guidance on technical requirements for regulated food and feed product applications to establish the presence of small particles including nanoparticles. This document sets out information requirements [...]
For nearly 15 years, trademarks and brand names that have existed in the EU before January 1, 2005 were granted a temporary exemption to the Nutrition and Health Claims Regulation (EC) No 1924/2006 (Article 27(2) NHCR). This means that names that imply a health claim, e.g. “Vital”, “Healthy” etc, were permitted to be used [...]
We dedicate this July issue to clinical research on infant nutrition and immune health, to the ending of the NHCR exemption for trademarks and brand names, and to EFSA’s open consultation on its technical draft for nanoparticles. Also, join us for our next webinar on the upcoming IVDR and prepare [...]
We dedicate this June issue to the on-going regulatory hurdles around CBD and the Commission evaluation regarding health claims on botanicals. […]
Recent regulatory news related to CBD worldwide. EU On June 8, 2020, two CBD novel food applications for synthetic Cannabidiol passed EFSA’s validity check. We look forward to more news. However, according to Vitafoods Insights and CBD-Intel, the progress on novel food authorizations for CBD-extracts (non-synthetic cannabinoids) will be paused until EU regulators decide [...]
Plants and their preparations are widely available on the EU market as foods or as herbal medicines, and their classification as “food” or medicine is of the responsibility of Member States. Thus, a plant substance classified as a “food” in one Member State, can be classified as “medicine” in another Member State. The European [...]
25 June 2020 – analyze & realize GmbH (a&r), the leading consulting and clinical research organization with specific focus on natural consumer health care products, is pleased to announce the appointment of Dr. Volker Schehlmann as new Managing Director. This appointment by the a&r shareholders is another step towards further strengthening the company with specific expertise [...]
We dedicate this May issue to thank you for joining us online during a&r virtual event and to provide an overview of recent CBD regulatory news worldwide. […]
CBD products are widely available, but their regulatory environment is not yet harmonized. Below you will find an overview of recent news related to CBD worldwide. EU In Europe, as of May 2020, four CBD applications have been submitted to the EU Commission. Only recently (31st March), the European Commission gave a mandate to [...]